Enanta Pharmaceuticals, Inc.ENTANASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year net income growth rate
Latest
-2.44%
↓ 194% below average
Average (39q)
2.60%
Historical baseline
Range
High:533.28%
Low:-176.36%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -2.44% |
| Q2 2025 | 19.38% |
| Q1 2025 | -1.59% |
| Q4 2024 | 22.67% |
| Q3 2024 | -27.21% |
| Q2 2024 | 27.28% |
| Q1 2024 | 6.74% |
| Q4 2023 | -18.86% |
| Q3 2023 | 28.05% |
| Q2 2023 | -3.74% |
| Q1 2023 | -29.92% |
| Q4 2022 | -10.01% |
| Q3 2022 | 16.88% |
| Q2 2022 | 5.63% |
| Q1 2022 | -11.55% |
| Q4 2021 | -22.42% |
| Q3 2021 | -2.39% |
| Q2 2021 | -8.98% |
| Q1 2021 | -164.71% |
| Q4 2020 | 71.62% |
| Q3 2020 | -105.69% |
| Q2 2020 | -137.55% |
| Q1 2020 | -144.67% |
| Q4 2019 | 46.26% |
| Q3 2019 | 30.63% |
| Q2 2019 | 69.75% |
| Q1 2019 | -84.06% |
| Q4 2018 | -5.14% |
| Q3 2018 | 35.15% |
| Q2 2018 | 61.59% |
| Q1 2018 | 7.37% |
| Q4 2017 | -67.97% |
| Q3 2017 | 533.28% |
| Q2 2017 | -56.27% |
| Q1 2017 | -8.27% |
| Q4 2016 | -176.36% |
| Q3 2016 | -67.47% |
| Q2 2016 | 34.59% |
| Q1 2016 | -106.28% |
| Q4 2015 | 350.60% |